The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma.
Gerald P. Linette
Consultant or Advisory Role - ZIOPHARM Oncology
Omid Hamid
Consultant or Advisory Role - ZIOPHARM Oncology
Research Funding - ZIOPHARM Oncology
Eric D. Whitman
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Jason Chesney
Research Funding - ZIOPHARM Oncology
Sanjiv S. Agarwala
No relevant relationships to disclose
Alexander Starodub
No relevant relationships to disclose
John A Barrett
Employment or Leadership Position - ZIOPHARM Oncology
Andrew Marsh
Employment or Leadership Position - ZIOPHARM Oncology
Stock Ownership - ZIOPHARM Oncology
Lori A. Martell
Employment or Leadership Position - ZIOPHARM Oncology
Angela Cho
Employment or Leadership Position - ZIOPHARM Oncology
Stock Ownership - ZIOPHARM Oncology
Thomas D. Reed
Employment or Leadership Position - Intrexon
Consultant or Advisory Role - Intrexon
Stock Ownership - Intrexon
Hagop Youssoufian
Employment or Leadership Position - ZIOPHARM Oncology
Consultant or Advisory Role - Intrexon
Stock Ownership - ZIOPHARM Oncology
Andrea Vergara-Silva
Employment or Leadership Position - ZIOPHARM Oncology